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Many different methods were developed to detect commonly known mutations and to screen new mutations of
the epidermal growth factor receptor in non-small cell lung cancer patients. Some of these methods are so
sensitive as to be able to detect even one epidermal growth factor receptor mutant tumor cell among up to 1000–
2000 normal cells. We have considered current methods chronologically reported to detect mutations in epidermal
growth factor receptor in patients with non-small cell lung cancer. We also gave a short preview of their
significance for routine clinical works. A Pub Med literature search was performed in order to demonstrate what
methods are mostly used in mutation detection and to show their distribution through the last 10 years.
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Introduction
An extensive genetic research has provided a lot of use-
ful information about molecular genetic abnormalities,
including chromosomal aberrations, over-expression of
oncogenes, and deletions or mutations in tumor su-
ppressor genes. These results have been applied to early
detection, classification, and prognosis of NSCLC [1].
Epidermal growth factor receptor (EGFR) is a trans-
membrane receptor protein with a ligand-binding
extracellular domain, trans-membrane domain, and
cytoplasmic tyrosine kinase (TK) domain. EGFR is a
member of a family of four tyrosine kinase receptor
(RTK) molecules. Several ligands bind with receptor(s)
and activate them inducing autophosporilation of TK
domain, which is usually affected with mutations. This
leads to a series of intracellular signaling pathways,
which in turn result in cancer proliferation, reduced
apoptosis, invasion, metastasis, and stimulation of
tumor-induced angiogenesis [1].* Correspondence: vdvd@mailcity.com
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distribution, and reproduction in any mediumNon-small cell lung cancer (NSCLC) is the most co-
mmon cause of cancer-related death in the world [2].
EGFR is over-expressed in several tumor types, including
NSCLC, and it was one of the molecules that were
recognized as a biomarker for the development of tar-
geted therapies [3,4]. The deletion of the four amino
acid sequence (del 746–750) in the exon 19 and the sub-
stitution of leucine by arginine at codon 858 (L858R) in
exon 21 are two of the most common mutations in the
kinase domain of EGFR gene in NSCLC patients [5].
The small-molecule tyrosine kinase inhibitors includ-
ing gefitinib and erlotinib have recently been approved
for the treatment of patients with NSCLC [4,6-9]. In
addition, mutations in the epidermal growth factor re-
ceptor (EGFR) have been confirmed as predictors of the
efficacy of treatment with EGFR-tyrosine kinase inhibi-
tors. The results from several randomized phase III trials
have emphasized the importance of molecular testing
prior to initiating first-line therapy for advanced NSCLC.
Increasing evidence demonstrates that patients with
EGFR mutations experience a more significant benefit
with gefitinib or erlotinib compared to standard chemo-
therapy, whereas an opposite effect occurred in patients
with EGFR-mutation negative tumors [7-9].
We have considered several methods to detect EGFR
mutation reported in literature and come into use in theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sophisticated novel methods and previewed their signifi-
cance for routine laboratory and clinical work.
Data review and interpretation
Pub Med literature was reviewed in May and April 2012
for all studies published from Jan 1, 2000 to December 31,
2011. In this search we took next key words: “mutations”,
“epidermal growth factor receptor”, “EGFR”, “non-small
cell lung cancer”, “NSCLC”, actually “mutations epidermal
growth factor receptor EGFR non-small cell lung cancer
NSCLC” in single search, with activated limits that
included “Humans”, “Cancer” and “Publication Date”. We
thus obtained 1,270 articles. Articles included in our ana-
lysis are presented in Figure 1.
We excluded reviews, reports (clinical trials, and case
reports), guidelines, editorials (editorial letters, news,
correspondences etc.), reports that were not in English
language or were not available, those which mismatched
our search terms (articles that discussed about other
proteins of mentioned signal pathways, not about EGFR,
or about other diseases) and articles published in 2012
(Figure 1).
Overview of current methods for detection mutations of
EGFR in NSCLC patients
Immunohistochemistry
Immunohistochemistry (IHC) is based on the binding of
antibodies tagged with a visible label to the specific an-
tigens in tissue sections [10]. Immunohistochemical a-
nalyses are routinely performed in clinical laboratories












Figure 1 Diagram of included and excluded articles (292 articles wereproteins or protein modifications. The advantage of this
technique for a wide use in clinical practice is the possi-
bility to preserve tumor morphology [11]. Immunohisto-
chemical method with monoclonal antibodies is much
easier and more cost-effective than analysis of extracted
DNA [12].
FISH assay (fluorescence in situ hybridization)
This is a method for detection of number of copies of
specific genes and location of the target sequences by
fluorescent label probe [13]. The main barriers to rou-
tinely performing FISH in clinical laboratories include
lack of availability in molecular techniques and of ex-
perience with the equipment for the dark-field fluores-
cence microscopy that is needed to assess copy number
[11,14].
One alternative to FISH might be chromogenic in situ
hybridization (CISH), which uses bright-field light micro-
scopic techniques to assess gene copy number and seems
to be accurate and reproducible at the same time [11,15].
High-performance liquid chromatography (HPLC)
Denaturing high performance liquid chromatography
(DHPLC) is another method to detect somatic and
inherited mutations [16]. NSCLC specimens were ana-
lyzed by high performance liquid chromatography on
the Transgenomic WAVE HS system by Jänne [17]. It is
a rapid method for EGFR mutation screening with 100%
sensitivity and without false negatives. It could detect
clinically relevant mutations in small diagnostic speci-
mens. Mutations in exons 18 to 21 of EGFR were ana-
lyzed using a DNA endonuclease, SURVEYOR, whichn English (86), not available (35), 
views (279), reports (clinical reports 
d case reports) (117), guidelines, 
itorials (editorial letters, news, 
rrespondences etc.) (51) cell lines 
2) miss match of search terms (334)
blished in 2012 (14)
chosen for analysis).
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analyses DNA could be prepared from both frozen and
formalin-fixed, paraffin-embedded (FFPE) tumor speci-
mens, without micro or gross dissection. This scanning
technique is superior to direct sequencing when used
with undissected formalin-fixed, paraffin-embedded spe-
cimens. Seven out of 160 (4%) mutations not previously
detected by direct sequencing could be detected using
SURVEYOR [17].
Cohen found advantages of DHPLC [18], like detec-
tion of mutations in exons 19 and 21, without resorting
to the digestion step described in the Jänne et al., which
makes this method less costly. Genotyping with this
technique can be done very rapidly. However, homozy-
gous mutation would miss this method and DHPLC
lacks the capacity to predict the exact nature of the
mutation. Therefore, subsequent verification by direct
sequencing would still be needed to identify the muta-
tion in positive cases [18].
Tan Min Chin developed a partially denaturing HPLC
(pDHPLC) assay [19] to detect a large range of sequence
variants with high sensitivity and low detection limits
for minority alleles in an inexpensive and standardized
manner. It is suggested as a useful approach for routine
detection of EGFR variants [19].
DNA sequencing
One of the sequencing methods, known as direct DNA
sequencing, is based on DNA synthesis in vitro having
four precursor nucleotides (NTP’s) and four deoxynu-
cleotides (ddNTP’s), one of which is often labeled in four
polymerase reactions [20]. It has now been developed an
automated sequencing and reactions are performed in a
single tube containing all four ddNTP's, each labeled
with a different color dye [21,22]. Also there are novel
methods of sequencing like pyrosequencing [23,24],
hybridization sequencing [25], and sequencing by de-
naturation [26].
Direct DNA sequencing of PCR-amplified genomic
DNA has been developed to detect EGFR mutations in
patient’s tumor tissue. Sensitivity of DNA sequencing is
affected with some steps. Biopsy treatment usually pro-
vides small amount of tissue, which is often not enough
amount of DNA for extraction from tumor samples. Par-
affinisation of tissues after biopsies is another step where
DNA could be lost, or it is a poor-quality for DNA se-
quencing regarding cross-contamination with DNA from
stromal cells. The quality of this method is affected by
the percentage of tumor cells in the sample and within
the mutation. Routine use of this method in clinical la-
boratories is still often limited by financial and technical
constraints and also by length of the procedure. It
requires a few days to obtain a result after tissue acquisi-
tion [15,27]. This method involves multiple steps (DNAextraction, PCR-based amplification, DNA sequencing,
and sequence interpretation). Sensitivity of direct
sequencing is suboptimal for clinical tumor samples;
mutant DNA needs to comprise ≥25% of the total DNA
to be easily detected [9].
Polymerase chain reaction The polymerase chain reac-
tion (PCR) is a rapid method used for exponential amp-
lification of a particular DNA sequence. PCR can be
extensively modified, and has a wide range of applica-
tions [28,29]. We describe here some usually applied
PCR techniques to diagnose EGFR mutations in NSCLC.
Reverse Transcription PCR (RT-PCR) is a method that
uses RNA as a template for an enzyme, reverse trans-
criptase that transforms RNA into cDNA which is then
amplified by regular PCR. RT-PCR is widely used to de-
termine the expression of a gene and does not require
post-PCR sample handling, preventing potential PCR
product contamination and resulting in much faster and
higher throughput assays [30,31].
Quantitative PCR(qPCR, also called real-time PCR) is
precisely a method used to measure the quantity of a
PCR product in a real-time. It is used to determine the
presence of a DNA sequence in a sample and the num-
ber of its copies in the sample. This qPCR uses fluorescent
dyes, such as Sybr Green, EvaGreen or fluorophore-
containing DNA probes, such as TaqMan, to measure the
amount of amplified product in real time [32,33].
The mutant-enriched PCR The mutant-enriched PCR
is a rapid and sensitive assay and it can detect one
mutant gene among as many as 103 to 104 copies of the
wild-type gene [34-36]. It eliminates wild-type genes se-
lectively and enriches the mutated genes, in two-step
PCR with intermittent restriction digestion [37].
This method can detect EGFR mutations in various
kinds of clinical samples including specimens by biopsies,
pleural fluid, and surgically resected tissues from patients
with NSCLC. But this assay can only be used to analyze
specific alterations containing a commonly deleted region
of exon 19 (codons 747–749) and the L858R mutation of
exon 21. It cannot detect minor alterations, like mutations
in exon 18, minor deletions of exon 19, and exon 20 inser-
tions [37]. False-positive result could occur within the
mutant-enriched PCR caused by high PCR cycle number.
It caused replacement of a critical nucleotide. Restriction
site of wild-type fragments could be destroyed. Results
were confirmed with the mutant-enriched PCR assay at
least twice and also performed sequencing to confirm the
EGFR alterations. This is an important and sensitive assay,
because it can detect commonly known mutations in hete-
rogeneous clinical samples that may contain a small frac-
tion of mutated genes and a large amount of wild-type
genes [37].
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PCR could be used in pleural effusion for screening EGFR
mutation in inoperable advanced NSCLC patients. The
results of comparing direct sequencing with mutant-
enriched PCR indicated that a significant portion of muta-
tions could be missed by using direct sequencing [38].
Peptide nucleic acid-locked nucleic acid (PNA-LNA)
PCR clamp PNA-LNA PCR clamp is a sensitive and
rapid method that was used for simultaneous detection
of 11 different EGFR mutations [39]. In addition, several
authors [40] screened about 30 non–small cell lung can-
cer cell lines, and among these established cell lines
from Japan people’s, eleven showed mutations. Briefly,
these results indicated that many cell lines have subpo-
pulations that hold specific EGFR mutations [40].
When using PNA clamp primers, amplification of the
wild-type sequences is suppressed, but amplification of
the mutant sequences is enhanced. LNA probes specifi-
cally detect mutant sequences in the presence of wild-type
sequences. Because PNA clamp primers have wild-type
sequences and LNA probes have mutant sequences, they
are located in the position. PNA clamp primers competi-
tively inhibit mutant LNA probes to bind to the wild type,
further increasing the specificity of detection. Thus, indi-
vidual EGFR mutations can be detected in the presence of
100- to 1,000-fold wild-type EGFR background molecules.
Researchers were multiplexed the reactions by using mul-
tiple probes labeled with different dyes to detect 11 muta-
tions by five reactions. Even after being multiplexed, each
mutation was detected in the presence of 100- to 1,000-fold
background [40].
Double-stranded PCR product formation assay per-
formed by Light Cycler This assay was performed by
Sasaki [41] who investigate EGFR mutation status in
Japanese lung cancer patients. The principle of this
method is measuring fluorescence of the SYBR Green
dye when it is intercalated in double-stranded DNA,
during PCR reaction, so it detects double-stranded PCR
product formation [41].
For the detection of mutations in very small amounts
of DNA is often used “nested PCR”, that is avoided by
using this assay. The advantage of this method is avoi-
ding ethidium bromide stain, which is potentially toxic
reagent. Researchers developed three different PCRs to
detect EGFR gene mutations and deletions. Three com-
mon EGFR mutations were analyzed, (in exon 18, a
G719S mutation, deletion in exon 19 and (CTG→ CGG;
L858R) mutation in exon 21) by real-time quantitative
PCR with mutation-specific sensor and anchor probes
[41].
Although researchers have only checked the three
most frequent mutations, this is a rapid method withoutneed for any post-PCR sample manipulation, which
saves time and minimizes the risks of DNA contamin-
ation. Double-stranded PCR product formation assay
performed by Light Cycleris is proposed for screening
and treatment evaluation, so it could be used in predict-
ing the sensitivity or resistance to TKI therapy for lung
cancer patients [41].
Polymerase chain reaction single-strand confor-
mation polymorphism (PCR-SSCP) In a study per-
formed by Marchetti [42], PCR-SSCP analysis was found
to be more sensitive than direct sequencing of PCR pro-
ducts, allowing identification of mutations that were
hardly detectable or undetectable (21% of cases) by di-
rect sequencing. Mutations missed by direct sequencing
were all point mutations. It was examined in NSCLC
patientsfor EGFR mutations in exons 18, 19, and 21
using a direct sequencing of polymerase chain reaction
products and PCR-SSCP analysis. More than 90% of the
mutations in the EGFR gene could be immediately
recognized by SSCP analysis. No false-positive or false-
negative results were obtained using the SSCP assay.
PCR-SSCP assay could be performed on formalin-fixed,
paraffin-embedded small biopsies [43], allowing the de-
tection of mutations from minimal amounts (<1 μg) of
starting DNA. The authors found three new mutations
(two new types of deletions and a new amino acid sub-
stitution at codon 858) and confirmed the presence of
several hot spot mutations [42].
Frequency of current methods reported in literature for
EGFR detection
We have presented numbers of published articles and
methods that were used for the set period of time (Figures 2
and 3). Immunohistochemical analyses (IHC), were not
used only as single methods but very often in combin-
ation with direct sequencing (DS), and/or fluorescence
in situ hybridization (FISH) and/or chromogenic in situ
hybridization (CISH). Also these combinations involved
peptide nucleic acid-locked nucleic acid (PNA-LNA)
PCR clamp for EGFR mutation analyses. Denaturing
high performance liquid chromatography (dHPLC) was
analyzed with direct sequencing, or even with some
additional methods like PCR, Scorpion Amplified Re-
fractory Mutation System technology (SARMS) [44].
Search criteria that included “polymerase chain reac-
tion” referred also to real time polymerase chain reac-
tion (or quantitative polymerase chain reaction) as well
as reverse transcription polymerase chain reaction.
Among novel PCR methods there are methods like:
cycleave real-time PCR [45], Scorpion Amplified Refrac-
tory Mutation System technology (SARMS) [46] or
nano-fluidic digital PCR arrays [47]. As novel methods





















Figure 2 Numbers of published articles and methods to detect mutations of EGFR in NSCLC patients through the years.
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biomagnetite [48], colorimetric detection of mutations
in EGFR using gold nano-particle aggregation [49] or de-
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Figure 3 Frequency of the methods used in the total selected periodThe distribution of methods used in ERGF mutation
detection for the set period of time is illustrated in
Figure 2. Immunohistochemical analyses in combination
with PCR, direct sequencing, FISH or CISH were more
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practice based on the consideration that protein expre-
ssion level can be evaluated directly on tumor cells or on
other specific cells of interest from formalin fixed and pa-
raffin embedded tissue. However, some subjectivism in
visual description contributes to the limitation of this
semiquantitative method [51]. The main lack of FISH
technology is an epifluorescent system, that could be over-
came with CISH which uses bright-field microscopy [51].
DNA sequencing, in the majority of the research paper
confirmed data analyzed previously by any other methods.
The advantage of PCR methods is that they enable the
analysis of a small tissue samples, like cells from body
fluids, bronchial washings, fine needle aspirates, as well as
circulating tumor cells.
DHPLC is used nowadays but often with direct se-
quencing. This method showed higher sensitivity when
compared to gene sequencing for most frequent muta-
tions of EGFR (deletion mutation and L858R mutation).
It was shown that the frequency of these mutations
detected by DHPLC was 30.1%, and that the analyses
were technically easier and less expensive for routine
clinical practice [44].
In the past six years direct sequencing, in combination
with PCR alone or with PCR and other advanced tech-
niques, has widely been used to detect EGFR mutation
in NSCLC. Recently, sensitive approaches to detect mu-
tation have been developed, including advanced PCR
methods, but they are less applied. PCR methods in
combination with highly sensitive methods usually need
confirmation by direct sequencing, but they allow mo-
difications and specialization, so it could be said they
are almost inevitable.
There are several differences in interpreting the in-
tensity of expression and the localization of receptors,
and the wide range of methods in use for EGFR detec-
tion, that causes heterogeneity of available reports [52].
So, there is no definitive conclusion and recommenda-
tion on which are the best methods to detect the muta-
tions of EGFR in NSCLC patients. Through the analysis
of the literature we gathered some problems that might
be helpful in the choice of methods to use: heteroge-
neity of the samples for analysis [15,37]; different types
of ligands that activate EGFR, and other members of
epidermal growth factor receptor family; plenty of signal
downstream pathways after receptors activation [53]; de-
velopment of resistance after TKIs treatment and appea-
rance of secondary mutations [54]; undefined and unclear
relation between EGFR over-expression and tumor inva-
siveness [55,56]; adverse effects of chemotherapy [57];
polymorphism of EGFR gene [58]. Non membrane bound
events and other mechanisms of increased signaling in the
modulation of specific behaviors should also be considered
[52]. There are certain efforts to provide universal scoringsystem and standardization of techniques and this is
discussed by Molecular Assays in NSCLC Working Group.
They recommend EGFR molecular assays for the use
and propose guidelines for tissue storage, handling, and
processing [11].
Conclusion
A lot of methods are used to determine mutations of
EGFR. These methods described here are highly sensi-
tive, but usually available to detect only commonly
known mutations of EGFR in NSCLC patients. DNA se-
quencing is widely used, but it is time-consuming and
sensitivity of this method is often concerned.
We wish to point out that certain methods described
here are generally used in the diagnosis of the tumor
from biopsy. Other more sensitive methods are recom-
mended to determine the presence of the mutation of
EGFR from small tissue quantities. EGFR gene copy
number can be assessed by a variety of methods, inclu-
ding FISH, CISH, and real-time quantitative PCR. Se-
veral publications reported up to 90% sensitivity for
detection of EGFR mutations in circulating tumor cells
isolated from patients with metastatic NSCLC [47,48].
However, to detect the presence of minimal residual
disease or molecular disease remission – thus solving a
big problem in the clinical practice - we would suggest
the need to introduce new, highly specific and more sen-
sitive methods constantly.Abbreviations
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